alanine has been researched along with Compensatory Hyperinsulinemia in 23 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Compensatory Hyperinsulinemia: A GLUCOSE-induced HYPERINSULINEMIA, a marker of insulin-resistant state. It is a mechanism to compensate for reduced sensitivity to insulin.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hypoglycemia in man induces a marked increase in hepatic amino- to urea-N clearance." | 3.70 | Hepatic amino- to urea-N clearance and forearm amino-N exchange during hypoglycemic and euglycemic hyperinsulinemia in normal man. ( Grøfte, T; Jørgensen, JO; Møller, N; Poulsen, PL; Vilstrup, H; Wolthers, T, 1999) |
| " This study determined the effect of arginine on plasma glucose and insulin regulation during endotoxicosis in order to assess its contribution to glucose dyshomeostasis in the pathogenesis of endotoxin shock." | 3.66 | Insulin hypersecretion and potentiation of endotoxin shock in the rat. ( Filkins, JP; Yelich, MR, 1982) |
| "Local hyperinsulinemia increased (P < 0." | 2.68 | Physiologic hyperinsulinemia stimulates protein synthesis and enhances transport of selected amino acids in human skeletal muscle. ( Biolo, G; Declan Fleming, RY; Wolfe, RR, 1995) |
| "For this purpose, a condition of hyperinsulinemia/hypoglycaemia was obtained with an intraperitoneal (ip) injection of regular insulin (1." | 1.35 | Evidence that L-glutamine is better than L-alanine as gluconeogenic substrate in perfused liver of weaned fasted rats submitted to short-term insulin-induced hypoglycaemia. ( Bazotte, RB; Curi, R; Felisberto-Junior, AM; Garcia, RF; Oliveira-Yamashita, F, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (30.43) | 18.7374 |
| 1990's | 7 (30.43) | 18.2507 |
| 2000's | 9 (39.13) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oliveira-Yamashita, F | 1 |
| Garcia, RF | 1 |
| Felisberto-Junior, AM | 1 |
| Curi, R | 1 |
| Bazotte, RB | 1 |
| Honka, MJ | 1 |
| Vänttinen, M | 1 |
| Iozzo, P | 1 |
| Virtanen, KA | 1 |
| Lautamäki, R | 1 |
| Hällsten, K | 1 |
| Borra, RJ | 1 |
| Takala, T | 1 |
| Viljanen, AP | 1 |
| Kemppainen, J | 1 |
| Pihlajamäki, J | 1 |
| Knuuti, J | 1 |
| Nuutila, P | 1 |
| Laakso, M | 1 |
| Jaziri, R | 1 |
| Lobbens, S | 1 |
| Aubert, R | 1 |
| Péan, F | 1 |
| Lahmidi, S | 1 |
| Vaxillaire, M | 1 |
| Porchay, I | 1 |
| Bellili, N | 1 |
| Tichet, J | 1 |
| Balkau, B | 1 |
| Froguel, P | 1 |
| Marre, M | 1 |
| Fumeron, F | 1 |
| Connolly, CC | 1 |
| Papa, T | 1 |
| Smith, MS | 1 |
| Lacy, DB | 1 |
| Williams, PE | 1 |
| Moore, MC | 2 |
| Yelich, MR | 1 |
| Filkins, JP | 1 |
| Simonson, DC | 1 |
| DeFronzo, RA | 1 |
| Eisemann, JH | 1 |
| Huntington, GB | 1 |
| Hamberg, O | 1 |
| Vilstrup, H | 2 |
| Biolo, G | 1 |
| Declan Fleming, RY | 1 |
| Wolfe, RR | 1 |
| Andrikopoulos, S | 1 |
| Proietto, J | 1 |
| Maggs, DG | 1 |
| Jacob, R | 1 |
| Rife, F | 1 |
| Caprio, S | 1 |
| Tamborlane, WV | 1 |
| Sherwin, RS | 1 |
| Jucker, BM | 1 |
| Rennings, AJ | 1 |
| Cline, GW | 2 |
| Shulman, GI | 3 |
| Grøfte, T | 1 |
| Wolthers, T | 1 |
| Jørgensen, JO | 1 |
| Poulsen, PL | 1 |
| Møller, N | 1 |
| McNulty, PH | 1 |
| Whiting, JM | 1 |
| Ebeling, P | 1 |
| Tuominen, JA | 1 |
| Laipio, ML | 1 |
| Virtanen, MA | 1 |
| Koivisto, E | 1 |
| Koivisto, VA | 1 |
| Ek, J | 1 |
| Andersen, G | 1 |
| Urhammer, SA | 1 |
| Hansen, L | 1 |
| Carstensen, B | 1 |
| Borch-Johnsen, K | 1 |
| Drivsholm, T | 1 |
| Berglund, L | 1 |
| Hansen, T | 1 |
| Lithell, H | 1 |
| Pedersen, O | 1 |
| Shiota, M | 1 |
| Galassetti, P | 1 |
| Monohan, M | 1 |
| Neal, DW | 1 |
| Cherrington, AD | 1 |
| Jensen, CB | 1 |
| Storgaard, H | 1 |
| Dela, F | 1 |
| Holst, JJ | 1 |
| Madsbad, S | 1 |
| Vaag, AA | 1 |
| Senior, B | 1 |
| Wolfsdorf, JI | 1 |
| Vidnes, J | 1 |
| Oyasaeter, S | 1 |
| Kreutner, W | 1 |
| Springer, SC | 1 |
| Sherwood, JE | 1 |
| Gruszczyńska, B | 1 |
| Tews, JK | 1 |
| Carter, SH | 1 |
| Stone, WE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| An Acute Randomized Dose-finding Equivalence Trial of Small, Catalytic Doses of Fructose and Allulose on Postprandial Carbohydrate Metabolism: The Fructose and Allulose Catalytic Effects (FACE) Study[NCT02459834] | 50 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
2 trials available for alanine and Compensatory Hyperinsulinemia
| Article | Year |
|---|---|
Effects of insulin and glucose on urea synthesis in normal man, independent of pancreatic hormone secretion.
Topics: Adult; Alanine; Amino Acids; Blood Glucose; Female; Glucagon; Glucose; Humans; Hyperglycemia; Hyperi | 1994 |
Physiologic hyperinsulinemia stimulates protein synthesis and enhances transport of selected amino acids in human skeletal muscle.
Topics: Adult; Alanine; Amino Acids; Biological Transport; Femoral Vein; Humans; Hyperinsulinism; Insulin; K | 1995 |
21 other studies available for alanine and Compensatory Hyperinsulinemia
| Article | Year |
|---|---|
Evidence that L-glutamine is better than L-alanine as gluconeogenic substrate in perfused liver of weaned fasted rats submitted to short-term insulin-induced hypoglycaemia.
Topics: Alanine; Animals; Fasting; Gluconeogenesis; Glucose; Glutamine; Glycerol; Hyperinsulinism; Hypoglyce | 2009 |
The Pro12Ala polymorphism of the PPARgamma2 gene is associated with hepatic glucose uptake during hyperinsulinemia in subjects with type 2 diabetes mellitus.
Topics: Adult; Alanine; Diabetes Mellitus, Type 2; Female; Humans; Hyperinsulinism; Male; Polymorphism, Gene | 2009 |
The PPARG Pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism: the Data From an Epidemiological Study on the Insulin Resistance
Topics: Adiponectin; Adult; Alanine; Amino Acid Substitution; Diabetes Mellitus; Genotype; Humans; Hyperglyc | 2006 |
Hepatic and muscle insulin action during late pregnancy in the dog.
Topics: 3-Hydroxybutyric Acid; Alanine; Animals; Blood Glucose; Dogs; Fatty Acids, Nonesterified; Female; Gl | 2007 |
Insulin hypersecretion and potentiation of endotoxin shock in the rat.
Topics: Alanine; Animals; Arginine; Blood Glucose; Homeostasis; Hyperinsulinism; Insulin; Insulin Secretion; | 1982 |
Glucagon physiology and aging: evidence for enhanced hepatic sensitivity.
Topics: Adult; Aged; Aging; Alanine; Female; Glucagon; Glucose; Glucose Tolerance Test; Humans; Hyperglycemi | 1983 |
Metabolite flux across portal-drained viscera, liver, and hindquarters of hyperinsulinemic, euglycemic beef steers.
Topics: Aging; Alanine; Animals; Biological Transport; Body Weight; Cattle; Glucose; Glucose Clamp Technique | 1994 |
The biochemical basis of increased hepatic glucose production in a mouse model of type 2 (non-insulin-dependent) diabetes mellitus.
Topics: Alanine; Animals; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dietary Fats; Disea | 1995 |
Counterregulation in peripheral tissues: effect of systemic hypoglycemia on levels of substrates and catecholamines in human skeletal muscle and adipose tissue.
Topics: Adipose Tissue; Adolescent; Adult; Alanine; Blood Glucose; Body Weight; Epinephrine; Extracellular S | 1997 |
13C and 31P NMR studies on the effects of increased plasma free fatty acids on intramuscular glucose metabolism in the awake rat.
Topics: Alanine; Animals; Carbon Isotopes; Fatty Acids, Nonesterified; Glucose; Glucose Clamp Technique; Glu | 1997 |
Hepatic amino- to urea-N clearance and forearm amino-N exchange during hypoglycemic and euglycemic hyperinsulinemia in normal man.
Topics: Adult; Alanine; Amino Acids; Blood Glucose; Forearm; Glucagon; Glucose Clamp Technique; Humans; Hype | 1999 |
Regulation of myocardial [(13)C]glucose metabolism in conscious rats.
Topics: Alanine; Animals; Blood Glucose; Carbon Isotopes; Citric Acid Cycle; Consciousness; Fasting; Glucose | 2000 |
Carbohydrate depletion has profound effects on the muscle amino acid and glucose metabolism during hyperinsulinaemia.
Topics: Adult; Alanine; Amino Acids; Amino Acids, Branched-Chain; Blood Glucose; Carbohydrates; Dietary Carb | 2001 |
Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians.
Topics: Aged; Alanine; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Tolerance Test; H | 2001 |
Inclusion of low amounts of fructose with an intraduodenal glucose load markedly reduces postprandial hyperglycemia and hyperinsulinemia in the conscious dog.
Topics: Alanine; Animals; Blood Glucose; Dogs; Duodenum; Fructose; Glucagon; Gluconeogenesis; Glucose; Glyce | 2002 |
Early differential defects of insulin secretion and action in 19-year-old caucasian men who had low birth weight.
Topics: 3-Hydroxybutyric Acid; Alanine; Birth Weight; Blood Glucose; C-Peptide; Denmark; Fatty Acids, Nonest | 2002 |
Hypoglycemia in children.
Topics: Adult; Alanine; Blood Glucose; Child; Fasting; Glucagon; Glucocorticoids; Gluconeogenesis; Growth Ho | 1979 |
Reduced gluconeogenesis due to hyperinsulinism: hormonal and metabolic studies in an infant with hypoglycemia.
Topics: Alanine; Child, Preschool; Fatty Acids, Nonesterified; Glucagon; Gluconeogenesis; Glycerol; Humans; | 1978 |
Resistance of gluconeogenic and glycogenic pathways in obese-hyperglycemic mice.
Topics: Alanine; Animals; Enzyme Activation; Female; Genotype; Gluconeogenesis; Glucose Tolerance Test; Glyc | 1975 |
[Changes in the alanine level in hypoglycemic states in children].
Topics: Alanine; Child; Child, Preschool; Female; Humans; Hyperinsulinism; Hypoglycemia; Infant; Male | 1987 |
Chemical changes in the brain during insulin hypoglycaemia and recovery.
Topics: Acetylcholine; Alanine; Amino Acids; Aminobutyrates; Ammonia; Animals; Aspartic Acid; Brain; Brain C | 1965 |